About us & our companies
Yaqrit’s founders are at the front line of treating patients with liver disease and pioneering new research in the field
Our discoveries are rooted in clinical practice based on deep understanding and experience of advanced liver disease
World-leading heritage and collaborations
Yaqrit’s heritage is built on 20 years of pioneering research by Professor Rajiv Jalan, a world-renowned hepatologist and Yaqrit’s Founder and CMO, and his colleagues at the UCL Liver Failure Group. Yaqrit actively partners to accelerate development of our innovative treatment solutions
2001
Founded by Prof Rajiv Jalan
$45m+
Investments to date in Yaqrit
>550+
Peer reviewed papers published
>55k+
Citations
60
Research Fellows
"Chronic liver disease is a huge global problem. At Yaqrit we are developing a pipeline of breakthrough product candidates designed to address each stage of advanced liver disease, from the clinic to intensive care."
Critical Discovery
Liver injury leads to increased leakage of bacterial endotoxins and toxic metabolites from the gut to the liver and to the extrahepatic organs leading to a cycle of inflammation, cell death and multiorgan failure. Our treatments hinge on this discovery targeting different aspects of the cycle
Bacterial endotoxins leak from gut to liver
Toxic metabolites such as ammonia accumulate
Inflammation
Leading to liver failure, inflammation, infection, encephalopahy and kidney failure
Our Companies
Yaqrit is developing life-saving medicines at an accelerated pace through focused, nimble subsidiaries dedicated to different targets, each addressing a specific medical need of advanced liver disease.
